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bacteraemia alone would be cost-saving. This latter study and recent 
evidence that the incidence of invasive pneumococcal msease is sim- 
llar in western Europe and the US support the use of pneumococcal 
vaccine as a public health measure. However, use has been limited 
in western Europe until the last few years. Since 1994 pneumococ- 
cal vaccine uptake has increased dramatically in Iceland, the UK, 
Sweden, Belgium and Norway. In other countries there has been 
little or no change. DBerences between countries in vaccine recom- 
mendations and reimbursement probably account for some of these 
KUiatiOnS. 
I S 193 I Prospects for New and Improved Influenza and 
Pneumococcal Vaccines 
D.S. Fedson. Pasteur Mhieux M S D ,  Lyon, France 
Interest in new and improved influenza and pneumococcal vaccines 
is widespread, but many difficulties must be overcome before they 
massive migration of populations in search of work or food; and 
collapse of already stmined public health h t r u c t u r e .  
Collapse of the public health h t r u c t u r e  is clearly demonstrated 
by the ongoing epidemic of dengue in Latin America, the result 
of a breakdown in mosquito control; and the amplification of the 
recent Ebola epidemic in Zaire, facilitated by sub-standard hospital 
mfection control practices. Recent importations of yellow fever into 
Switzerland and the United States attest to the intensity of inter- 
national travel for pleasure, while deforestation and irrigation may 
provide the opportunities for vectors of viral pathogens to reproduce 
in ever greater numbers. 
In the world of today viral pathogens will continue to emerge and 
reemerge, but reinforced surveillance, laboratories and public health 
dastructure will ensure their early detection and control. 
m] Old and Newly Discovered European Hantavirus 
Infections 
are introduced. Live attenuated influenza vaccines are immunogenic 
and well tolerated and &cal trials are underway in chddren. How- 
ever, they may be useful in older adults only to supplement current 
inactivated vaccines. Several adjuvanted d u e n z a  vaccines are be- 
ing tested &cally, but in many instances their increased immuno- 
genicity has been oftset by increased side effects. Influenza DNA 
vaccines are of greatest interest. Experimental studies show that im- 
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munization with the DNA of internal protein (NF') and surface (H) 
antigens elicits protection against heterotypic dection (presumably 
NP-mediated) as well as antibodies to the homotypic H antigens, 
and Phase I c h i d  trials have recently begun. For pneumococ- 
cal vaccines, studies in chddren have shown that conjugate vaccines 
(PCV) are immunogenic, prime for booster responses to polysac- 
charide (PV) vaccine and reduce naso-pharyngeal carriage. Similar 
immunogenicicy and priming have been demonstrated in adults. EU- 
perimental protein-based (e.g., PspA, pneumolysin) vaccines promise 
to be cross-protective against many different capsular type pneumo- 
coccal infections, but have not been directly compared to PV or 
PCV. The future clinical utility of new or improved influenza and 
pneumococcal vaccines appears promising for children, whereas the 
advantages they will offer over current vaccines in the elderly may 
be marginal. Their greatest promise may lie in the immunization of 
older children and non-elderly adults, persons hitherto not consid- 
ered candidates for either vaccine. 
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I S194 1 Emerging Viral Pathogens 
D.L. Heymann. The World Health Organization Division o f E m q ' n g  
and Other Communicable Diseases Surveillance and Control (EMC), 
Avenue Appia, Geneva, Switzerland 
Emerging viral pathogens such as sin nombre or Ebola provide ev- 
idence of the ability of viral pathogens to cross the species barrier 
to man, while others such as hepatitis C and HIV highlight their 
insidious nature. Several factors contribute to the emergence and or 
recognition'of new viruses. Most can be linked directly or indirectly 
to the increasing numbers of people living on the earth. The re- 
sult is intenslfication in international travel for business or pleasure; 
increased exposure to disease vectors and reservoirs in areas once 
d b i t e d ;  changes in ecology with deforestation and irrigation; 
In Europe hantaviruses infecting humans include Puumala virus 
causing mild hemorrhagx fever with renal syndrome 
(HFRS) also known as nephmpathia epidemica (NE), Dobrava and 
probably Hantaan (causing severe HFRS) and Seoul viruses (caus- 
ing HFRS). These infections may be conveniently diagnosed using 
IgG, I@ and IgG-avidity enzyme immunoassays based on the use 
of capture antibodies and recombinant baculovirus-expressed PUU 
and HTN nucleocapsid proteins. In addition, using immunological 
screening of rodents followed by PCR, genetic analysis and subse- 
quent virus isolation, we have discovered Tula virus (TUL.) h m  Eu- 
ropean common voles and Topografov virus (TOP) &om lemmings. 
We have shown that TUL can d e c t  humans but the pathogenicity 
of TUL and TOP are not yet known. Phylogenetic analyses show 
that (i) hantaviruses are coevolving with their ~ t u r a l  carrier rodents, 
(ii) genetic variants are clustered according to their geographic origin 
and (iii) hantaviruses in individual hosts are represented as complex 
mixtures of closely related genetic and antigenic variants (quasis- 
pecies). Our results show that the severity of NE is associated with 
HLA B8 DR3 haplotype and correlates with the relative ease of 
RT-PCR detection of PUU sequences h m  patient blood and urine. 
In contrast, HLA B27 is associated with a mild course of NE. 
I S196 I Community respiratory virus infections in 
immunocompromised patients. When the trivial 
becomes fatal 
E. Whunbey. The Univenity of Z x a  M .  D. Anderson Cancer Center, 
Houston, TX, USA 
Community respiratory viruses (CRV) have emerged as a major 
cause of life-threatening pneumonia in immunocompromised pa- 
tients. Recent studies have revealed that a minimum of 20%-30% 
of patients with leukemia and BMT recipients hospitalized with an 
acute respiratory illness are infected with a CRV (respiratory syn- 
o/tlal virus, influenza viruses, parainfluenza viruses, adeno-viruses, 
picornaviruses). Approximately 60% of these infections are com- 
plicated by pneumonia, with an associated mortality of 50%. The 
illnesses range from seemingly trivial upper respiratory illnesses to 
fatal pneumonias (and occasionally other organ disease) depending 
largely on the type of virus, and the type, degree and duration of 
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immunodeficiency. The pneumonias may be primarily viral, bacte- 
rial/fungal, or mixed. RSV has been associated with an exceptionally 
high frequency of the progression to fatal viral pneumonia in some 
subsets of patients. The mortality of untreated RSV pneumonia in 
these patients has been > 80%. Studies have suggested that the early 
initiation of therapy with a combination of aerosolized ribavirin and 
M G  may be of benefit. Influenza has been associated with a some- 
what lower frequency of progression to f a d  wal pneumonia than 
RSV, however, the spectrum of vulnerable patients has been broader. 
Because of the large number of immunocompromised patients seri- 
ously ill with CRV diseases, effective prophylactic and therapeutic 
regimens need to be defined expeditiously. This will be a challenge 
given the diversity of viruses and their widespread prevalence and 
contagiousness; the lirmted means of rapid dqnosis; the paucity 
of prophylactic and therapeutic options; and the wide spectrum of 
immunocompromised patients with varying vulnerability to serious 
CRV disease. 
I S 197 I Risk assessment and response in suspected 
imported cases of viral haemonhagic fevers 
D. Bennett. Communicable Disease Surwillance Cenhe, London, UK 
V d  hemorrhagic fevers (VHF) are infkquently seen outside their 
countries of origin, but cases have occasionally been imported into 
Europe, the U.S., Oceania, and recently South Africa. During the 
period of an outbreak in the country of origin, other countries 
may experience panic, inappropriate responses by officials and others 
dealing with well and ill immigrants/traders, delays in diagnosis 
and treatment of patients with other &eases, and unnecessary lab- 
oratory tests, isolation, and surveillance procedures in misclassified 
suspect cases. Over 95% of suspected imported VHF cases have had 
a final dqnosis of malaria. On the other hand, unclear or nonexis- 
tent policies can also lead to lack of communication between public 
health personnel, infectious disease physicians, microbiologists, im- 
migration officials, and the public, and to delays in ordering appro- 
priate tests, isolation, treatment, and surveillance of contacts when 
a VHF should be suspected. Policies should ensure coordinated ef- 
forts for prompt recognition of suspected cases leading to appropriate 
clinical, laboratory, transport, public health, and media responses, but 
also for prevention of inappropriate suspicion and responses. 
Specific guidance has been developed in the U.K. for management 
and control of VHF, focusing on those that are trammissible person 
to person. Policy areas include risk assessment, patient management, 
specimen handling, laboratory procedures, and public health actions. 
The discussion will focus on this guidance and examples of U.K. 
coordinated actions to deal with the possibility of imported cases 
during recent outbreaks of VHF in Atiica. It is suggested that coun- 
tries should consider communication procedures to coordinate the 
work of clinical personnel with other sectors. It is useful for all hos- 
pitals to have policies known to all relevant staff for the management 
of patients with a pyrexia of unknown origin or a suspected VHF, 
and procedures for communication with public health officials, spe- 
ualist clinicians and laboratories, and high security infectious disease 
units when appropriate. Cases in which a VHF is to be ruled out 
can be classified by "risk category", and suggested procedures will 
be discussed for each level of risk. Basic patient information to be 
collected will be listed, and flow charts for handling of patients and 
specimens based on risk category will be set out. 
Pneumococci: The resistance challenge 
I S198 I Emergence of Internationally-Spread 
Multidrug-Resistant (MDR) Clones of 
Streptococcus pneumoniae 
A. Tomasz. The Rockefeller Unim'ty, Nk; Nk; USA 
I shall discuss three aspects of MDR pneumococci. (i) The "biolog- 
ical price" of resistance. Laboratory mutants of pneumococci with the 
same basic molecular mechanism of penicillin resistance as the one 
identified in resistant isolates recovered fiom the clinical environ- 
ment have a multiplicity of physiologicalhiochemical defects which 
are absent fiom the clinical resistant bugs. New experiments have 
begun to rhrow some light on the nature of these extra "fimess" 
factors present in clinical isolates (but not in laboratory mutants) of 
resistant pneumococd that allow expression of antibiotic resistance 
without jeopardizing normal physiology. (ii) Acquisition and exchange 
ofgenetic material will be dustrated by results documenting the ubiq- 
uitous presence of competence (for genetic transformation) genes 
within the species, and by new experiments documenting in vivo 
exchange of capsular genes in MDR pneumococci. (iii) Properties 
of 3 internationally-spread MDR clones of S. pneumoniae will be 
summarized includmg clone-spec& properties such as the structure 
of the resistant PBP genes; unique protein polymorphism of PBPs, 
unique chromosomal macrorestriction fingerprints and unique cell 
wall composition. An update on the geographic expansion of these 
international clones will be provided fiom prevalence data that in- 
clude both invasive as well as colonizing isolates. 
I S199 I Genomic Analysis of Streptococcuspneumoniae 
P Matsushima, R.H. Balm, E Norris, B.S. DeHoff, F! R o c k ,  
G. Porter, S. Burgett, R. Peery, J. Hoskins, L. Braverman, 
I. Jenkins, F! Solenberg, M. Young-Behdo, M. Mdienney, J. Tang, 
EL. Skatrud, PR. Rosteck, S.R. Jaskunas. f i l ly Research Laboratories, 
Eli fi l ly G Co.,  Indiana 46285, USA 
Effective therapy for upper-respiratory infections has become 
compromised in recent years by the emergence of strains that are 
resistant to commonly used antibiotics such as penicillin. In partic- 
ular, the wide-spread occurrence of penicillin-resistant Streptocm 
pneumonia has become a major concern. To discover new antibiotics 
that could be used to treat these infections we have initiated a 
project to identlfy novel targets in S. pneumoniae that are also found 
in other organisms responsible for upper-respiratory infections 
such as Haemophilus infuenzae. Possible targets are being identified 
by random DNA sequence analysis of the S. pneumoniae genome. 
Sample sequencing has been used to idenafy genes, which have been 
mapped to different Smd m e n 6  of the c d a r  chromosome 
and compared to orthologous genes in other organisms. I n r e d  
segments of the genes are being used for insertional mutagenesis 
to determine if any particular gene is required for viability. An 
unconventional procedure was developed for these 'knock-out' 
experiments, which will be described along with the results of the 
sequence analysis. 
I s200 I The EfFect of Antimicrobial Use on the 
Epidemiology of Penicillin Resistant 
Pneumococci in Children 
K.G. Kritinsson. National University Hospital, Reykjavik, Iceland 
P e n i c h  resistant and multiresistant pneumococci have spread glob- 
ally and reached high predence rates in many countries. Antimi- 
crobial use is considered to be a major driving force for resistance in 
